Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) yesterday floated a joint promotion aimed at luring users of the Animas insulin pump after Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. The companies are hoping to chip off a piece of the diabetes market from Medtronic (NYSE:MDT), to which J&J has offered to help some 90,000 Animas patients transfer (J&J is also evaluating another […]
Drug-Device Combinations
UK design firm touts new device as “the Nespresso of auto-injectors”
People living with chronic diseases often have to treat themselves at home using a medical device like an auto-injector. The process can be nerve-wracking, because it requires the patient to follow a number of important steps – like properly storing their drugs and warming them to the correct temperature at the time of injection. These […]
How etectRx’s “smart pill” aims to improve patient compliance trends
When Harry Travis first met Neil Euliano and learned about his medication adherence technology, the pharmaceutical industry was beginning to usher in the age of pricey drugs with Hepatitis C therapies that hit the market at prices like $500 or $1,000 dollars a pill. “It just so happened at the time, really expensive medications were […]
Anika’s Monovisc therapy gets green light in Australia
Anika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints. This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. The Bedford, Mass.-based company said it plans […]
Adventist Health System to use Glytec’s diabetes management system at 39 acute care facilities
Glytec has partnered with Adventist Health System to bring its eGlycemic diabetes management system to 39 of the health system’s acute care facilities. Glytec’s cloud-based eGMS will become a part of the standard of care for patients who need insulin therapy, in both the critical care units and on the medical-surgical floor, the companies said. Get […]
Researchers combine a smart phone, insulin pump and CGM in diabetes study
In a study published this week in Diabetes Care, researchers combined an insulin pump, a continuous glucose monitoring receiver and a smart phone with cloud-based algorithms to automatically monitor and adjust a patient’s glucose levels. The team pointed towards a number of systems that are designed to function as an artificial pancreas, but still require that […]
Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came in […]
OptiNose IPO pulls in $120m
OptiNose (NSDQ:OPTN) raised $120 million with its initial public offering last week, adding $20 million to the target is set earlier this month. Yardley, Penn.-based OptiNose floated 7.5 million shares at $16 apiece in the offering, above the range it set Oct. 3 for 6.3 million shares at $15 to $17 apiece. Get the full story at our sister […]
Insulet shareholder sues over OmniPod Eros
Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually caused the shares in the company to plummet. Carnazza named a number of former and current executives in the suit, […]
Reva Medical launches Fantom in Switzerland with first implant of bioresorbable scaffold
Reva Medical (ASX:RVA) has expanded its commercial operations into Switzerland, the company said today, with the first implant of its Fantom bioresorbable scaffold. The scaffold is made from Reva’s tyrosine-derived, radiopaque polymer, rendering Fantom visible under fluoroscopy – a characteristic that is unique to Reva’s product. Get the full story at our sister site, Drug Delivery […]
FDA advisory committee backs Aerie’s Rhopressa eye drug
An FDA advisory committee voted today in favor of Aerie Pharmaceuticals‘ (NSDQ:AERI) Rhopressa product candidate. The dermatologic and ophthalmic drugs advisory committee voted unanimously that clinical trials support the efficacy of Aerie’s netarsudil ophthalmic solution for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nine members of the committee voted to say […]